{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:49Z","timestamp":1779923629622,"version":"3.53.1"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOST108-2314-B-037"],"award-info":[{"award-number":["MOST108-2314-B-037"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH108-8R05"],"award-info":[{"award-number":["KMUH108-8R05"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMU-TC108A04-3"],"award-info":[{"award-number":["KMU-TC108A04-3"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMU-TC108B06"],"award-info":[{"award-number":["KMU-TC108B06"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMU-TC108B07, KMU-DK109002"],"award-info":[{"award-number":["KMU-TC108B07, KMU-DK109002"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background\/Aims<\/jats:title>\n<jats:p>Undetectable HCV RNA 12 weeks after the end of treatment (SVR12) has been the valid efficacy endpoint in the era of direct-acting antivirals (DAAs). Its concordance with SVR4 and SVR24 and long-term durability is unknown in Taiwanese chronic hepatitis C (CHC) patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 1080 CHC patients who received all-oral DAAs and an achieved end-of-treatment virological response (EOTVR), defined as undetectable HCV RNA at the end of therapy, were consecutively enrolled. HCV RNA was monitored 4, 12, and 24 weeks after EOT. Patients who achieved SVR24, defined as undetectable HCV RNA 24 weeks after EOT, were followed annually for assessing SVR durability.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Eleven (1.02%) patients experienced HCV RNA reappearance after EOT. The most frequent timing of RNA reappearance was observed at SVR4 (n = 7), followed by SVR12 (n = 3) and SVR 24 (n = 1). The positive predictive value (PPV) and negative predictive value (NPV) of SVR4 in predicting SVR12 were 99.7% and 100%, respectively, whereas the PPV and NPV of SVR12 in predicting SVR24 were 99.9% and 100%, respectively. Pyrosequencing confirmed delayed relapse rather than reinfection for the patient who had detectable HCV RNA at SVR24. Among 978 patients who achieved SVR24, after a median follow-up period of 17.3\u00b18.2 months, the SVR durability is 100% up to a 4-year follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Achievement of SVR12 provides excellent durability of HCV seroclearance after DAA therapy. On-demand HCV RNA beyond SVR12 should be recommended for patients with unexplainable abnormal liver function or high-risk behaviors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0245479","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:55:28Z","timestamp":1612533328000},"page":"e0245479","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-6418","authenticated-orcid":true,"given":"Chuan-Pin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Cheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-I","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ju","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-130X","authenticated-orcid":true,"given":"Tyng-Yuang","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":true,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"issue":"5","key":"pone.0245479.ref001","doi-asserted-by":"crossref","first-page":"e026703","DOI":"10.1136\/bmjopen-2018-026703","article-title":"Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study","volume":"9","author":"CF Huang","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"pone.0245479.ref002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pone.0245479.ref003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2014.02.022","article-title":"Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication","volume":"61","author":"CF Huang","year":"2014","journal-title":"J Hepatol"},{"issue":"7","key":"pone.0245479.ref004","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-16-0921","article-title":"Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis c virus patients: a model for prioritization of treatment","volume":"23","author":"ML Yu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"pone.0245479.ref005","first-page":"S0168-8278(17)32273-0","author":"GN Ioannou","year":"2017","journal-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma J Hepatol"},{"issue":"4","key":"pone.0245479.ref006","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10620-014-3050-5","article-title":"All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C","volume":"59","author":"E Dieperink","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"24","key":"pone.0245479.ref007","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"AJ van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"pone.0245479.ref008","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for Chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"ML Yu","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"pone.0245479.ref009","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"ML Yu","year":"2007","journal-title":"Gut"},{"issue":"5","key":"pone.0245479.ref010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12072-019-09974-z","article-title":"Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium","volume":"13","author":"CF Huang","year":"2019","journal-title":"Hepatol Int"},{"issue":"1","key":"pone.0245479.ref011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"EM Yoshida","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"pone.0245479.ref012","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies","volume":"64","author":"C Sarrazin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0245479.ref013","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/liv.13596","article-title":"Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens","volume":"38","author":"KR Reddy","year":"2018","journal-title":"Liver Int"},{"issue":"6","key":"pone.0245479.ref014","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population","volume":"119","author":"ML Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"pone.0245479.ref015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations","volume":"119","author":"ML Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"pone.0245479.ref016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcv.2011.07.007","article-title":"Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C","volume":"52","author":"J Vermehren","year":"2011","journal-title":"J Clin Virol"},{"issue":"2","key":"pone.0245479.ref017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"L Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"issue":"7","key":"pone.0245479.ref018","first-page":"362","article-title":"The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases","volume":"32","author":"YH Lin","year":"2016","journal-title":"Kaoshiung J Med Sci"},{"issue":"2","key":"pone.0245479.ref019","first-page":"154","article-title":"Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review","volume":"15","author":"SV Burgess","year":"2016","journal-title":"Ann Hepatol"},{"issue":"2","key":"pone.0245479.ref020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0245479.ref021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"AASLD-IDSA Hepatitis C Guidance Panel","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"pone.0245479.ref022","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/cid\/cix457","article-title":"Hepatitis C Virus Relapse 78 Weeks After Completion of Successful Direct-Acting Therapy","volume":"65","author":"C Boschi","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:55:49Z","timestamp":1612533349000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245479"}},"subtitle":[],"editor":[{"given":"Luis M.","family":"Schang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245479","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}